Delivery Order SPE2DB20D2014-SPE2DB25FC75N
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $22,972.76 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 14, 2025, with completion expected by August 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $18,029.12 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed price terms with an ultimate completion date of September 5, 2025. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $4,253.28. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $32,444.88 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of September 2, 2025, with performance to be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $24,779.66 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded contract—not utilizing any set-aside designation—will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC75NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger vehicle—specifically AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems. The company's extensive contract portfolio with DLA encompasses a broad range of pharmaceutical products, medical devices, and specialty medications across multiple therapeutic domains. This particular delivery order for Dupixent—a biologic medication used to treat conditions such as eczema, asthma, and chronic rhinosinusitis—supports the Defense Health Agency and other federal healthcare systems' ongoing pharmaceutical supply requirements. The company's consistent receipt of non-set-aside, competitively awarded contracts demonstrates its capability to meet rigorous federal procurement standards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.3k | 8/14/25 |